8x8 Inc vs IQVIA Holdings Inc. Common Stock — how do they compare? 8x8 Inc trades at $2.1 (market cap $311.98M), while IQVIA Holdings Inc. Common Stock trades at $259.95 (market cap $42.61B). The key difference: IQVIA Holdings Inc. Common Stock is far larger — about 136.6× 8x8 Inc's market cap, and IQVIA Holdings Inc. Common Stock is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and IQVIA Holdings Inc. Common Stock for 1 Days on average.
| EGHT | IQV | |
|---|---|---|
Market Cap | $311.98M | $42.61B |
Volume | 1,639,086 | 988,398 |
Sector | Technology | Health |
52-Week High | $2.76 | $275.02 |
52-Week Low | $1.59 | $156.66 |
Typical Hold Time | 16 Days | 1 Days |
Enterprise Value | $578.90M | $56.77B |
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.11, down 1.4% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $27.21 million in 2025 despite revenue of $715.07 million, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights cost-saving wins for clients and AI product growth, with a consensus analyst price target of $19.77 suggesting significant upside potential from current levels.
The outlook hinges on the company's ability to translate top-line growth into sustained profitability. While valuation multiples like a P/S of 0.42 appear attractive, a high P/E of 72 and substantial long-term debt of $338.37 million present risks. The primary opportunity is execution on its financial model to achieve positive net income, as projected for 2026.
No Aura AI signal available yet.
Trailing returns across standard periods
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →IQVIA provides clinical research, healthcare data, technology, and consulting services to life sciences companies. Its work supports drug development and commercialization.
Read more on IQV →